Literature DB >> 16297161

Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts.

D Hormdee1, T Nagasawa, M Kiji, R Yashiro, H Kobayashi, G Koshy, K Noguchi, H Nitta, I Ishikawa.   

Abstract

Periodontitis, a chronic inflammatory disease, is characterized by increased expression of interleukin (IL)-1 and other inflammatory mediators resulting in extensive osteoclast formation and bone loss. Expression of receptor activator of nuclear factor kappa B ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), by osteoblasts is important to regulate osteoclast differentiation. The aim of the present study was to investigate the regulatory effects of IL-1 on RANKL and OPG production by mesenchymal fibroblasts in periodontal tissue. Human gingival fibroblasts (HGF) and periodontal ligament fibroblasts (PDL) were stimulated with IL-1alpha with or without protein synthesis inhibitor cycloheximide (CHX), protein kinase A (PKA) inhibitors, protein kinase C (PKC) inhibitors and prostaglandin E(2) (PGE(2)) inhibitor. In some experiments, the cultured cells were directly stimulated with either PKA or PKC activators. In HGF, IL-1alpha-stimulated OPG mRNA expression was high and could be reduced by CHX. PKA inhibitor completely abrogated IL-1alpha-induced OPG mRNA expression and OPG production. Endogenous PGE(2) further enhanced IL-1alpha-induced OPG production in HGF. In PDL, RANKL mRNA expression was greatly augmented by IL-1alpha. IL-1alpha induced OPG mRNA expression and protein production. PKC inhibitor partially reduced IL-1alpha-induced OPG production and PKC activator enhanced OPG production in PDL. The IL-1alpha-stimulated OPG mRNA expression in HGF was greater than PDL. These results provide new evidence for the possible osteoclastogenesis-inhibitory function of HGF through PKA activity pathway. PDL utilized PKC for OPG production. Thus, we emphasize that HGF and PDL have different characteristics of host defence mechanism against inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297161      PMCID: PMC1809540          DOI: 10.1111/j.1365-2249.2005.02937.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  IL-1 signal transduction.

Authors:  E Muñoz Blanco
Journal:  Immunol Today       Date:  1991-08

2.  Involvement of cyclic AMP-dependent protein kinases in the signal transduction pathway for interleukin-1.

Authors:  M Chedid; S B Mizel
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

3.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Authors:  E Tsuda; M Goto; S Mochizuki; K Yano; F Kobayashi; T Morinaga; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1997-05-08       Impact factor: 3.575

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population.

Authors:  B A Scheven; J W Visser; P J Nijweide
Journal:  Nature       Date:  1986 May 1-7       Impact factor: 49.962

Review 6.  The interleukin-1 family: 10 years of discovery.

Authors:  C A Dinarello
Journal:  FASEB J       Date:  1994-12       Impact factor: 5.191

7.  IL-1 activates two separate signal transduction pathways in T helper type II cells.

Authors:  E Muñoz; U Beutner; A Zubiaga; B T Huber
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

8.  Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6.

Authors:  Y H Zhang; J X Lin; Y K Yip; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  Elevated cAMP is required for stimulation of eicosanoid synthesis by interleukin 1 and bradykinin in BALB/c 3T3 fibroblasts.

Authors:  R M Burch; J R Connor
Journal:  J Cell Physiol       Date:  1992-06       Impact factor: 6.384

10.  Cyclic adenosine 3',5'-monophosphate, a second messenger in interleukin-1 mediated K562 cytostasis.

Authors:  M N Weitzmann; N Savage
Journal:  Biochem Biophys Res Commun       Date:  1993-01-29       Impact factor: 3.575

View more
  5 in total

1.  Porphyromonas gulae Activates Unprimed and Gamma Interferon-Primed Macrophages via the Pattern Recognition Receptors Toll-Like Receptor 2 (TLR2), TLR4, and NOD2.

Authors:  James A Holden; Neil M O'Brien-Simpson; Jason C Lenzo; Rebecca K H Orth; Ashley Mansell; Eric C Reynolds
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

2.  Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide.

Authors:  M Kiji; T Nagasawa; D Hormdee; R Yashiro; H Kobayashi; K Noguchi; H Nitta; Y Izumi; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2007-06-05       Impact factor: 4.330

3.  Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease.

Authors:  Mikihito Kajiya; Gabriela Giro; Martin A Taubman; Xiaozhe Han; Marcia P A Mayer; Toshihisa Kawai
Journal:  J Oral Microbiol       Date:  2010-11-08       Impact factor: 5.474

4.  The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis.

Authors:  Muhanad Ali; Nathan Kucko; John A Jansen; Fang Yang; X Frank Walboomers
Journal:  Clin Oral Investig       Date:  2020-06-06       Impact factor: 3.573

Review 5.  Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.

Authors:  Sarah Sohyun Park; Aleksandra Uzelac; Joanne Kotsopoulos
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.